Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Universitas Airlangga
Modality
UNKNOWN
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
72High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07570368CT.gov Targeting Stress-Driven Inflammatory and Angiogenic Pathways With Brief ACT to Enhance Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT06966700CT.gov A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | — | Recruiting | — | — | — |
NCT06797635CT.gov Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) | — | Recruiting | — | — | — |
NCT05485766CT.gov Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT06312176CT.gov A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | — | Recruiting | — | — | — |
NCT06121570CT.gov Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer | — | Recruiting | — | — | — |
NCT05978648CT.gov Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy | — | Recruiting | — | — | — |
NCT05981014CT.gov Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer | — | Recruiting | — | — | — |
NCT05862610CT.gov The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC | — | Not Yet Recruiting | — | — | — |
NCT05020860CT.gov Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer | — | Recruiting | — | — | — |
Show 20 more trialsShow fewer
NCT05582499CT.gov Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | — | Recruiting | — | — | — |
NCT05253066CT.gov Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer | — | Unknown | — | — | — |
NCT04895358CT.gov Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) | — | Active Not Recruiting | — | — | — |
NCT04660929CT.gov CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | — | Unknown | — | — | — |
NCT04373031CT.gov Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04561362CT.gov Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | — | Active Not Recruiting | — | — | — |
NCT04059003CT.gov CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer | — | Unknown | — | — | — |
NCT03756090CT.gov The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer | — | Unknown | — | — | — |
NCT03556358CT.gov Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer | — | Completed | — | — | — |
NCT03272477CT.gov Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients | — | Completed | — | — | — |
NCT03018080CT.gov Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer | — | Completed | — | — | — |
NCT02952989CT.gov A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT02513472CT.gov Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) | — | Completed | — | — | — |
NCT02395627CT.gov Reversing Therapy Resistance With Epigenetic-Immune Modification | — | Terminated | — | — | — |
NCT00448305CT.gov EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients | — | Completed | — | — | — |
NCT02181101CT.gov Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial | — | Completed | — | — | — |
NCT00110695CT.gov Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer | — | Completed | — | — | — |
NCT00525642CT.gov Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer | — | Unknown | — | — | — |
NCT00242203CT.gov Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer | — | Completed | — | — | — |
NCT00174707CT.gov Study of Docetaxel in Breast Cancer Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Epirubicin (this asset) | Universitas Airlangga | Approved | BB · 69 |
| Adriamycin | Merck Sharp & Dohme LLC | P4 | BB |
| Letrozole | Fujian Cancer Hospital | P4 | BB |
| Tamoxifen | Eli Lilly and Company | P3 | BB |
| Docetaxel | Universitas Airlangga | P4 | BB |
| Cyclophosphamide | Merck Sharp & Dohme LLC | P4 | BB |
| Exemestane | Fujian Cancer Hospital | P4 | BB |
| Microporous Polysaccharide Hemospheres | Fundación para la Investigación del Hospital Clínico de Valencia | P4 | BB |
| Eribulin Monomethanesulfonate | Fudan University | P4 | BB |
+42 more in the Breast Neoplasm cohort
Other indications for Epirubicin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Inflammatory Breast Carcinoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Epirubicin in Breast Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/epirubicin-breast-neoplasm-125142
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →